Evidence map›Paper›PMID 39498543›Full record

ArticleCirculation. Heart failure2024

Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.

Usman A Tahir, Paul Kolm, Raymond Y Kwong, Milind Y Desai, Sarahfaye F Dolman, Shuliang Deng, Evan Appelbaum, Patrice Desvigne-Nickens, John P DiMarco, Gaurav Tiwari and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Hypertrophic Cardiomyopathy: Current Perspectives.Reviews in cardiovascular medicine · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Usman A TahirDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (U.A.T., S.D., E.A., G.T., R.E.G.).ORCID 0000-0002-3657-6082
Paul KolmDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, United Kingdom (P.K., S.K.P., H.W., S.N.).ORCID 0000-0003-2653-5452
Raymond Y KwongDepartments of Medicine, Radiology, and Pathology, Brigham and Women's Hospital, Boston, MA (R.Y.K., M.J.-H., P.J., C.Y.H.).ORCID 0000-0001-8212-0759
Milind Y DesaiHeart, Vascular and Thoracic Institute, Cleveland Clinic, OH (M.Y.D).ORCID 0000-0003-0010-9797
Sarahfaye F DolmanMedStar Heart and Vascular Institute, Washington, DC (S.F.D., J.H.Z.-P., W.S.W.).ORCID 0000-0003-3651-9069
Shuliang DengDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (U.A.T., S.D., E.A., G.T., R.E.G.).ORCID 0000-0002-1543-2733
Evan AppelbaumDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (U.A.T., S.D., E.A., G.T., R.E.G.).
Patrice Desvigne-NickensNational Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., D.-Y.K.).ORCID 0000-0003-1073-641X
John P DiMarcoCardiovascular Division, University of Virginia Health System, Charlottesville (J.P.D., C.M.K.).
Gaurav TiwariDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (U.A.T., S.D., E.A., G.T., R.E.G.).ORCID 0009-0000-2540-6005
Matthias G FriedrichMcGill University, Montreal, QC, Canada (M.G.F.).ORCID 0000-0003-1204-5647
Julissa H Zelaya-PortilloMedStar Heart and Vascular Institute, Washington, DC (S.F.D., J.H.Z.-P., W.S.W.).ORCID 0009-0006-2465-9039
Michael Jerosch-HeroldDepartments of Medicine, Radiology, and Pathology, Brigham and Women's Hospital, Boston, MA (R.Y.K., M.J.-H., P.J., C.Y.H.).ORCID 0000-0001-9018-6731
Dong-Yun KimNational Heart, Lung, and Blood Institute, Bethesda, MD (P.D.-N., D.-Y.K.).ORCID 0000-0001-9405-4840
Martin S MaronLahey Hospital and Medical Center, Burlington, MA (M.S.M.).ORCID 0000-0002-9923-3853
Stefan K PiechnikDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, United Kingdom (P.K., S.K.P., H.W., S.N.).ORCID 0000-0002-0268-5221
Jeanette Schulz-MengerCharité Experimental Clinical Research Center and Helios Clinics Berlin-Buch, Germany (J.S.-M.).ORCID 0000-0003-3100-1092
Hugh WatkinsDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, United Kingdom (P.K., S.K.P., H.W., S.N.).ORCID 0000-0002-5287-9016
William S WeintraubMedStar Heart and Vascular Institute, Washington, DC (S.F.D., J.H.Z.-P., W.S.W.).ORCID 0000-0002-5384-5571
Stefan NeubauerDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, United Kingdom (P.K., S.K.P., H.W., S.N.).ORCID 0000-0001-9017-5645
Christopher M KramerCardiovascular Division, University of Virginia Health System, Charlottesville (J.P.D., C.M.K.).ORCID 0000-0003-2057-7731
Petr JarolimDepartments of Medicine, Radiology, and Pathology, Brigham and Women's Hospital, Boston, MA (R.Y.K., M.J.-H., P.J., C.Y.H.).ORCID 0000-0002-9612-8652
Robert E GersztenDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (U.A.T., S.D., E.A., G.T., R.E.G.).ORCID 0000-0002-6767-7687
Carolyn Y HoDepartments of Medicine, Radiology, and Pathology, Brigham and Women's Hospital, Boston, MA (R.Y.K., M.J.-H., P.J., C.Y.H.).ORCID 0000-0002-7334-7924
HCMR Investigators

Funding

HCMR Novel Markers of Prognosis in Hypertrophic CardiomyopathyU01HL117006 · NHLBI · UNIVERSITY OF VIRGINIA · PI KRAMER, CHRISTOPHER M., NEUBAUER, STEFAN · 2013 to 2017
$14.5M
The Role of SECTM1 in Monocyte Biology and AtherosclerosisK08HL161445 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Usman A. Tahir · 2022 to 2026
$822k
NHLBI NIH HHS K08 HL161445NHLBI NIH HHS U01 HL117006
6 · The paper itself

Abstract

backgroundHypertrophic cardiomyopathy (HCM) is a heterogeneous condition that can lead to atrial fibrillation, heart failure, and sudden cardiac death in many individuals but mild clinical impact in others. The mechanisms underlying this phenotypic heterogeneity are not well defined. The aim of this study was to use plasma proteomic profiling to help illuminate biomarkers that reflect or inform the heterogeneity observed in HCM.

methodsThe Olink antibody-based proteomic platform was used to measure plasma proteins in patients with genotype positive (sarcomeric) HCM participating in the HCM Registry. We assessed associations between plasma protein levels with clinical features, cardiac magnetic resonance imaging metrics, and the development of atrial fibrillation.

resultsWe measured 275 proteins in 701 patients with sarcomeric HCM. There were associations between late gadolinium enhancement with proteins reflecting neurohormonal activation (NT-proBNP [N-terminal pro-B-type natriuretic peptide] and ACE2 [angiotensin-converting enzyme 2]). Metrics of left ventricular remodeling had novel associations with proteins involved in vascular development and homeostasis (vascular endothelial growth factor-D and TM [thrombomodulin]). Assessing clinical features, the European Society of Cardiology sudden cardiac death risk score was inversely associated with SCF (stem cell factor). Incident atrial fibrillation was associated with mediators of inflammation and fibrosis (MMP2 [matrix metalloproteinase 2] and SPON1 [spondin 1]).

conclusionsProteomic profiling of sarcomeric HCM identified biomarkers associated with adverse imaging and clinical phenotypes. These circulating proteins are part of both established pathways, including neurohormonal activation and fibrosis, and less familiar pathways, including endothelial function and inflammatory proteins less well characterized in HCM. These findings highlight the value of plasma profiling to identify biomarkers of risk and to gain further insights into the pathophysiology of HCM.

Indexed as

Atrial FibrillationBiomarkersCardiomyopathy, HypertrophicProteomicsAdultAgedFemaleHumansMaleMiddle AgedRegistriesSarcomeresVentricular RemodelingBiomarkersbiomarkerscardiomyopathy, hypertrophiccoronary artery diseaseheart failureproteomics

Identifiers

PMID39498543
PMCPMC11652235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.